Company Filing History:
Years Active: 2012-2014
Title: Innovations of Nicholas Perl in Cancer Research
Introduction
Nicholas Perl is a notable inventor based in New York, NY, who has made significant contributions to the field of cancer research. He holds two patents that focus on the synthesis and application of triterpene saponins, which are crucial in developing immuno-adjuvants for vaccines.
Latest Patents
His latest patents include innovations related to triterpene glycoside saponin-derived adjuvants. The inventions detail methods of synthesis and their uses, particularly highlighting QS-7, a potent immuno-adjuvant that is significantly less toxic than QS-21. QS-21 is currently favored in anticancer and antiviral vaccines. Perl's work addresses the challenges posed by tedious isolation and purification protocols that have hindered the clinical development of QS-7. He provides a novel semi-synthetic method that utilizes a hydrolyzed prosapogenin mixture to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to these compounds for preclinical and clinical evaluation.
Career Highlights
Nicholas Perl is affiliated with the Sloan Kettering Institute for Cancer Research, where he continues to advance his research in immunology and vaccine development. His work is pivotal in enhancing the efficacy and safety of cancer treatments through innovative adjuvant technologies.
Collaborations
Throughout his career, Perl has
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.